Rafael Holdings Inc News - RFL

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer

Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer PR Newswire NEWARK, N.J., Oct. 6, 2021 NEWARK, N.J...

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 PR Newswire NEWARK, N.J., Sept. 17, 2021...

Rafael Holdings Announces $104.2 Million Private Placement

Rafael Holdings Announces $104.2 Million Private Placement PR Newswire NEWARK, N.J., Aug. 20, 2021 NEWARK...

Rafael Holdings Expands Leadership Team with Three Highly Experienced Global Biopharmaceutical Executives to Build a Fully Integrated Cancer Metabolism Therapeutics Company

Rafael Holdings Expands Leadership Team with Three Highly Experienced Global Biopharmaceutical Executives to...

Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Rand...

CRANBURY, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a...

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer

CRANBURY, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a...

Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference ...

Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health...

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the...

CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a...

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08 PR Newswire NEWARK, N.J., April 16, 2021...

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) fo...

CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”...

Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”...

Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a...

Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for SHMT Inhibitor P...

Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for...

UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Mye...

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a...

Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leuk...

CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Rafael Holdings Inc (RFL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

RFL News

Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Holdings Announces $104.2 Million Private Placement

Rafael Holdings Expands Leadership Team with Three Highly Experienced Global Biopharmaceutical Executives to Build a Fully Integrated Cancer Metabolism Therapeutics Company

Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Rand...

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer

Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference ...

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the...

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) fo...

Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for SHMT Inhibitor P...

UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Mye...

Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leuk...

RFL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Rafael Holdings Inc (RFL) News

Rafael Holdings Inc (RFL)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

RFL News

Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Holdings Announces $104.2 Million Private Placement

Rafael Holdings Expands Leadership Team with Three Highly Experienced Global Biopharmaceutical Executives to Build a Fully Integrated Cancer Metabolism Therapeutics Company

Rafael Pharmaceuticals to Present Pancreatic & Biliary Tract Cancer Data on CPI-613® (Devimistat) from its Multicenter, Rand...

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (Devimistat) for Treatment of Biliary Cancer

Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference ...

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the...

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) fo...

Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference

Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Barer Institute Announces Licensing Agreement with Princeton University's Office of Technology Licensing for SHMT Inhibitor P...

UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Mye...

Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leuk...

RFL Discussion

Your Recent History